切换导航
  • 比较产品

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。

main product photo

EasySep™ Release人CD3正选试剂盒

采用可解离磁珠技术的免疫磁珠正选
只有 %1 左
率先评论此产品
¥11,970.00
添加并比较

产品号 #（选择产品）

产品号 #17751_C

采用可解离磁珠技术的免疫磁珠正选

产品优势

  • 只需不到30分钟，分选出高纯度的人CD3+细胞

产品组分包括

  • EasySep™ Release人CD3正选试剂盒(产品号 #17751)
    • EasySep™ Release人CD3正选抗体混合物,1 mL 
    • EasySep™ Releasable RapidSpheres™ 50201磁珠 ,1 mL 
    • EasySep™ Release缓冲液（浓缩）, 3 x 1 mL 
  • RoboSep™ 人CD3正选试剂盒 (产品号 #17751RF)
    • EasySep™ Release人CD3正选抗体混合物, 1 mL
    • EasySep™ Releasable RapidSpheres™ 50201磁珠, 1 mL
    • EasySep™ Release缓冲液（浓缩）, 3 x 1 mL
    • RoboSep™ 缓冲液（产品号 #20104）
    • RoboSep™ 过滤吸头 (产品号 #20125)
立即询价
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. EasySep™磁极
    EasySep™磁极
  2. EasySep™缓冲液
    EasySep™缓冲液
总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

EasySep™ Release人CD3正选试剂盒用于从新鲜或冻存的人外周血单个核细胞 (PBMC) 或洗涤的白细胞单采术样本中分离出高纯度的CD3+细胞。 该试剂盒使用识别CD3表面标志物的抗体复合物和EasySep™ Releasable RapidSpheres™可解离磁珠来正选CD3+细胞。目的细胞用抗体和磁珠标记，并通过 EasySep™ 磁极进行无柱分选。非目的细胞通过简单倾倒弃去，而目的细胞则保留在试管中。然后，结合在EasySep™分离的CD3+细胞上的磁珠被解离，这些细胞可立即用于下游应用，例如流式细胞术、细胞培养或DNA/RNA提取。使用该EasySep™ Release试剂盒分选之后，细胞表面仍结合有抗体复合物，并可能与Brilliant Violet™偶联的抗体、聚乙二醇修饰的蛋白质或其他化学相关配体相互作用。

磁极兼容性
• EasySep™磁极（产品号 #18000）
• “The Big Easy” EasySep™磁极（产品号 #18001）
• EasyPlate™ EasySep™磁极（产品号 #18102）
• EasyEights™ EasySep™磁极（产品号 #18103）
• RoboSep™-S（产品号 #21000）
 
分类
细胞分选试剂盒
 
细胞类型
T 细胞
 
种属
人
 
样本来源
白细胞单采术样本、PBMC
 
分选方法
正选
 
品牌
EasySep，RoboSep
 
研究领域
免疫，细胞治疗开发
 

查看更多 显示更少

实验数据

Typical EasySep™ Release Human CD3 Positive Selection Profile

Figure 1. Typical EasySep™ Release Human CD3 Positive Selection Profile

Starting with a single-cell suspension of human PBMCs, the CD3+ cell content of the isolated fraction is typically 98.7 ± 0.9% (mean ± SD) using the purple EasySep™ Magnet. In the above example, the purities of the start and final isolated fractions are 38.4% and 99.0%, respectively.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
产品说明书
Product Name
RoboSep™ Release人CD3正选试剂盒
Catalog #
17751RF
Lot #
All
Language
中文
Document Type
产品说明书
Product Name
EasySep™ Release人CD3正选试剂盒
Catalog #
17751
Lot #
All
Language
中文
Document Type
Product Information Sheet
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Product Information Sheet
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
EasySep™ Release Human CD3 Positive Selection Kit
Catalog #
17751
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Product Name
RoboSep™ Release Human CD3 Positive Selection Kit
Catalog #
17751RF
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (11)

T Cell Reagents for Your Cellular Therapy Research
Brochure
T Cell Reagents for Your Cellular Therapy Research
EasySep™ Cell Separation Technology
Brochure
EasySep™ Cell Separation Technology
EasySep™ Release Free Your Positively Selected Cells from Magnetic Particles
Brochure
EasySep™ Release Free Your Positively Selected Cells from Magnetic Particles
Tools for Your Immunology Research
Brochure
Tools for Your Immunology Research
Production of Chimeric Antigen Receptor T Cells
Wallchart
Production of Chimeric Antigen Receptor T Cells
Frequencies of Human Cell Types in Blood-Related Sources
Wallchart
Frequencies of Human Cell Types in Blood-Related Sources
Human Immune Cytokines
Wallchart
Human Immune Cytokines
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
1:57
Video
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
CAR T Cell Manufacturing Workflow: Isolation, Activation and Expansion
0:59
Video
CAR T Cell Manufacturing Workflow: Isolation, Activation and Expansion
Simultaneous Cell Isolation from Multiple Samples Using the EasyEights™ EasySep™ Magnet
0:57
Video
Simultaneous Cell Isolation from Multiple Samples Using the EasyEights™ EasySep™ Magnet
Releasable RapidSpheres Enable Immunomagnetic Purification of Highly Viable and Functional Immune Cells from Complex Tissues in Less Than 30 Minutes
Scientific Poster
Releasable RapidSpheres Enable Immunomagnetic Purification of Highly Viable and Functional Immune Ce...

文献 (2)

Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). N. Allende-Vega et al. Scientific reports 2022 jan

Abstract

Solid tumor cells have an altered metabolism that can protect them from cytotoxic lymphocytes. The anti-diabetic drug metformin modifies tumor cell metabolism and several clinical trials are testing its effectiveness for the treatment of solid cancers. The use of metformin in hematologic cancers has received much less attention, although allogeneic cytotoxic lymphocytes are very effective against these tumors. We show here that metformin induces expression of Natural Killer G2-D (NKG2D) ligands (NKG2DL) and intercellular adhesion molecule-1 (ICAM-1), a ligand of the lymphocyte function-associated antigen 1 (LFA-1). This leads to enhance sensitivity to cytotoxic lymphocytes. Overexpression of anti-apoptotic Bcl-2 family members decrease both metformin effects. The sensitization to activated cytotoxic lymphocytes is mainly mediated by the increase on ICAM-1 levels, which favors cytotoxic lymphocytes binding to tumor cells. Finally, metformin decreases the growth of human hematological tumor cells in xenograft models, mainly in presence of monoclonal antibodies that recognize tumor antigens. Our results suggest that metformin could improve cytotoxic lymphocyte-mediated therapy.
View publication
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. X. Wang et al. Leukemia 2022 apr

Abstract

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent antitumor effects in B-cell malignancies including acute lymphoblastic leukemia (ALL), but antigen loss remains the major cause of treatment failure. To mitigate antigen escape and potentially improve the durability of remission, we developed a dual-targeting approach using an optimized, bispecific CAR construct that targets both CD19 and BAFF-R. CD19/BAFF-R dual CAR T cells exhibited antigen-specific cytokine release, degranulation, and cytotoxicity against both CD19-/- and BAFF-R-/- variant human ALL cells in vitro. Immunodeficient mice engrafted with mixed CD19-/- and BAFF-R-/- variant ALL cells and treated with a single dose of CD19/BAFF-R dual CAR T cells experienced complete eradication of both CD19-/- and BAFF-R-/- ALL variants, whereas mice treated with monospecific CD19 or BAFF-R CAR T cells succumbed to outgrowths of CD19-/BAFF-R+ or CD19+/BAFF-R- tumors, respectively. Further, CD19/BAFF-R dual CAR T cells showed prolonged in vivo persistence, raising the possibility that these cells may have the potential to promote durable remissions. Together, our data support clinical translation of BAFF-R/CD19 dual CAR T cells to treat ALL.
View publication
View All Publications

更多信息

更多信息
物种 人
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyPlate™ Magnet (Catalog #18102) • EasyEights™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
样本来源 PBMC, 白细胞单采术样本
Selection Method Positive
标记抗体
  1. 抗人CD4抗体，clone OKT4
    抗人CD4抗体，clone OKT4

    小鼠Monoclonal IgG2b抗体，抗人、恒河猴、食蟹猴CD4

  2. 抗人CD8a抗体，clone RPA-T8
    抗人CD8a抗体，clone RPA-T8

    小鼠Monoclonal IgG1抗体，抗人、恒河猴、食蟹猴CD8a

  3. 山羊抗小鼠IgG (H+L)抗体，Polyclonal
    山羊抗小鼠IgG (H+L)抗体，Polyclonal

    抗小鼠IgG（H+L）山羊Polyclonal抗体

  4. 抗人CD3抗体，clone UCHT1
    抗人CD3抗体，clone UCHT1

    小鼠（BALB/c）Monoclonal IgG1抗体，抗人、黑猩猩CD3

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
Copyright © 2026 by STEMCELL Technologies. All rights reserved.

在线联系